PMET Resources has completed over 30,000 meters of drilling across 250+ holes at its 100%-owned Shaakichiuwaanaan Project in Quebec during 2026. The drilling program focuses on supporting mine development, including geotechnical and hydrogeological assessments, and aims to define a maiden caesium Mineral Resource Estimate at the CV5 pegmatite by late 2027. Results from the program will feed into updated feasibility studies and resource estimates scheduled for release in late 2026 and 2027, reinforcing the project's potential as a significant source of lithium, tantalum, and caesium. Assay results are expected in Q1 2027, with drilling continuing into November 2026.
PMET Resources' Shaakichiuwaanaan development progress provides context for Basic Materials sector activity. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 21, 2026 03:36 WIB: Of 83 priced US stocks, 36 rose and 46 fell today. Notable movers include CENX at USD 33.44 with a 1-day change of -2.68% and 100% sell order activity, SLI at USD 1.50 with a 1-day change of +2.38% and 100% buy order activity, and AUGO at USD 83.99 with a 1-day change of -2.37%.
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
